Verastem - Turnaroundspekulation 2016
Mal sehen, was bei dem Kurs / Kursverlauf alles passieren kann!
Pipeline:
http://www.verastem.com/products/
Aktueller Kurs: 1,58 +0,15 +10,49 % in USD
https://www.businesswire.com/news/home/20210920005200/en/
•Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months.
•11 of 24 (46%) patients treated with the combination achieved a confirmed partial response (PR). Of the 11 patients with KRAS mutant LGSOC, 7 (64%) achieved a confirmed PR.
•Combination continues to exhibit a favorable tolerability profile.
•Top-line results from the selection portion of Verastem’s registration-directed Phase 2 RAMP 201 LGSOC study expected during the first half of 2022.
https://finance.yahoo.com/news/...updated-investigator-153000366.html
https://investor.verastem.com/financial-information/sec-filings
https://money.cnn.com/quote/quote.html?symb=VSTM
https://investor.verastem.com/news-releases/...2021-financial-results
Zahlen für Q4/21
- Umsatz 0,5 Mio. $
- Verlust 16,5 Mio. $
- Cash 100 Mio. $
- MK 234 Mio. $
- Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC;
- Expected Cash Runway Through 2025 to Support Continued Development and Potential Commercial Launches of VS-6766 and Defactinib
- Enrollment Complete in Selection Phase (Part A) of RAMP 201 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer; Expect to Report Results from Part A in 2Q 2022
- Enrollment Complete in Selection Phase (Part A) of RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of KRAS G12V Mutant Non-Small Cell Lung Cancer; Expect to Report Results from Part A in 2H 2022
https://investor.verastem.com/news-releases/...ter-and-full-year-2021
Durch das Funding mit Oxford wird VSTM wieder interessanter, beobachte ich weiter, Alert bei 1,00$
https://ih.advfn.com/...;width=800&vol=1&height=400&Vol=1
https://www.benzinga.com/news/22/04/26628716/...ces-price-target-of-5
Zahlen für Q2/22
- keine Umsätze
- Verlust 22 Mio. $
- Cash 94 Mio. $
- MK 173 Mio. $
- expects that it has a cash runway until at least 2025
https://investor.verastem.com/news-releases/...2022-financial-results
Update
- Results of Part A of RAMP 202 Trial in KRAS G12V-Mutant NSCLC Show VS-6766 ± Defactinib Did Not Meet Criteria to Continue to Expansion Phase
https://investor.verastem.com/news-releases/...66-clinical-trials-and
Zahlen für Q4/22
- keine Umsätze
- Verlust 17 Mio. $
- Cash 88 Mio. $
- MK 83 Mio. $
https://investor.verastem.com/news-releases/...ter-and-full-year-2022
Zahlen für Q1/23
- kein Umsatz
- Verlust 16 Mio. $
- Cash 111 Mio. $
- MK 81 Mio. $
https://investor.verastem.com/news-releases/...2023-financial-results
https://finance.yahoo.com/news/...t-verastem-oncologys-210500253.html
https://finance.yahoo.com/news/...ounces-reverse-stock-131100164.html
Trotz einer solchen Meldung ein verdammt starker bzw. stabiler Kursverlauf.
1/12 RS
https://investor.verastem.com/news-releases/...es-reverse-stock-split
Vorbörslich -10% auf 11$
...The revolutionary treatment has been shown to significantly shrink tumours in almost half of patients with the disease
...The new treatment blocks tumour growth, helping keep the disease at bay for years. Experts said the “fantastic” and “very exciting” results from clinical trials of the drug combination, presented at the world’s largest cancer conference this weekend, showed it was “far more effective” than any available option for patients.
...The phase 2 trial, led by the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, tested the drug avutometinib alone and in combination with defactinib in 29 patients.
Trial results show almost half the patients on the new drug combination – 45% – saw their tumours shrink significantly. It proved to be almost twice as effective as the next best treatment – trametinib, which has a response rate of 26%.
https://www.theguardian.com/science/2023/jun/03/...ancer-breakthrough
85 Mio. $ Offering
- u.a. 7,18 Mio. neue Aktien zu je 9,75$
Verastem Oncology beabsichtigt, den Nettoerlös aus dem öffentlichen Angebot für:
- (i) die fortgesetzte Forschung und Entwicklung seiner Produktkandidaten
- (ii) die potenzielle Einführung von avutometinib und defactinib bei niedriggradigem serösem Eierstockkrebs und
- (iii) das Betriebskapital und andere allgemeine Unternehmenszwecke zu verwenden
https://investor.verastem.com/news-releases/...illion-public-offering